Jump to content

Main menu Navigation ●Main page ●Contents ●Current events ●Random article ●About Wikipedia ●Contact us ●Donate Contribute ●Help ●Learn to edit ●Community portal ●Recent changes ●Upload file

●Create account ●Log in ●Create account ● Log in Pages for logged out editors learn more ●Contributions ●Talk

(Top) 1 References

Ordesekimab

Add links ●Article ●Talk ●Read ●Edit ●View history Tools Actions ●Read ●Edit ●View history General ●What links here ●Related changes ●Upload file ●Special pages ●Permanent link ●Page information ●Cite this page ●Get shortened URL ●Download QR code ●Wikidata item Print/export ●Download as PDF ●Printable version Appearance From Wikipedia, the free encyclopedia

Ordesekimab is an anti-interleukin 15 monoclonal antibody developed by Amgen to treat refractory celiac disease.^[1]^[2]^[3]^[4]

References[edit]

^ Cellier, Christophe; Bouma, Gerd; van Gils, Tom; Khater, Sherine; Malamut, Georgia; Crespo, Laura; Collin, Pekka; Green, Peter H R; Crowe, Sheila E; Tsuji, Wayne; Butz, Eric; Cerf-Bensussan, Nadine; Macintyre, Elizabeth; Parnes, Jane R; Leon, Francisco; Hermine, Olivier; Mulder, Chris J; Jabri, Bana; Murray, Joseph; DiMarino, Anthony; Kelly, Ciaran P; Byrnes, Valerie; Sanders, David; Lundin, Knut EA; Schumann, Michael; Bontkes, Hetty; Meresse, Bertrand; Roy Ariño, Garbiñe; Bhagat, Govind; Viiri, Keijo; Rounioja, Samuli; Bui, Jack; Perez Maseda, Raquel; García-Hoz, Carlota; Trinquand, Amelie; Vlad, George; Hadjivassiliou, Marios; Azizi, Michel; Blanchard, Anne; Llewellyn, Beth; Palmer, Ashleigh; Raymond, Ralph (December 2019). "Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study" (PDF). The Lancet Gastroenterology & Hepatology. 4 (12): 960–970. doi:10.1016/S2468-1253(19)30265-1.

^ Lähdeaho, Marja-Leena; Scheinin, Mika; Vuotikka, Pekka; Taavela, Juha; Popp, Alina; Laukkarinen, Johanna; Koffert, Jukka; Koivurova, Olli-Pekka; Pesu, Marko; Kivelä, Laura; Lovró, Zsófia; Keisala, Joni; Isola, Jorma; Parnes, Jane R; Leon, Francisco; Mäki, Markku (December 2019). "Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study". The Lancet Gastroenterology & Hepatology. 4 (12): 948–959. doi:10.1016/S2468-1253(19)30264-X.

^ Wei, Yu-Ling; Wegesser, Teresa; Kuhns, Scott; Werner, Jonathan; Lebrec, Hervé; Wang, Xiaoting (31 December 2022). "Strategies to evaluate potential effector function of glycan variants: A case study of ordesekimab (AMG 714 or PRV-015)" (PDF). Journal of Immunotoxicology. 19 (1): 109–116. doi:10.1080/1547691X.2022.2113841.

^ Ciccocioppo, Rachele; Caprnda, Martin; Kruzliak, Peter (December 2019). "Blocking interleukin 15: a light at the end of the tunnel?". The Lancet Gastroenterology & Hepatology. 4 (12): 896–898. doi:10.1016/S2468-1253(19)30293-6.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Ordesekimab&oldid=1205082756" Categories: ●Anti-interleukin monoclonal antibodies ●Pharmacology stubs Hidden categories: ●Orphaned articles from November 2023 ●All orphaned articles ●All stub articles ●This page was last edited on 8 February 2024, at 20:38 (UTC). ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization. ●Privacy policy ●About Wikipedia ●Disclaimers ●Contact Wikipedia ●Code of Conduct ●Developers ●Statistics ●Cookie statement ●Mobile view